Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules (NCT07226804) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules
United States30 participantsStarted 2026-04-26
Plain-language summary
To observe the outcomes of nsPFA therapy to treat benign thyroid nodules.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Eligibility Criteria
* Scheduled to undergo ultrasound guided nsPFA as standard of care
* Age 18 to 80 years.
* Capable of providing independent consent.
* Presence of biopsy-confirmed benign thyroid nodule , defined as one of the following:
* Benign FNA X 2 or
* Benign US guided FNA X 1 + benign thyroid nodule ultrasound appearance (TI-RADS 2) or
* Benign FNA X 1 and radiographic/laboratory evidence of functional nature
* Nodule measuring \>2cm in greatest dimension
* Presence of compressive symptoms reasonably attributable to thyroid nodule (i.e. pressure sensation, dysphagia, dysphonia, respiratory distress)
* No abnormal cervical lymph nodes during screening visit .
Exclusion Criteria
* Age \<18
* Patients considered unsuitable for nsPFA by the treating physician
What they're measuring
1
Quality-of-life Questionnaire
Timeframe: Through study completion; an average of 1 year